“…54,55 The data regarding clopidogrel use in higher risk endoscopic procedures is more limited. 56,57 In contrast to aspirin, which irreversibly inhibits platelet cyclooxygenase activity, thus preventing the synthesis of prostaglandins and thromboxane A 2 , 58 clopidogrel blocks platelet aggregation by irreversibly inhibiting the adenosine phosphateinduced activation of the platelet fibrinogen (glycoprotein IIb/IIIa) receptor. 59 Like aspirin, clopidogrel irreversibly inhibits platelet function, and its antiplatelet effects can persist for 7 to 10 days after stopping the drug.…”